Category: Healthcare and Medical News
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
Fourth IND Application approval for investigational extracellular vesicle (EV) product ExoFlo
Extracellular vesicle product ExoFlo clinical trials to address early-stage COVID-19.
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct Biologics Product Line
The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial.